NCT05940896View on ClinicalTrials.gov

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 29, 2023

Primary Completion Date

November 16, 2024

Study Completion Date

February 28, 2027

Conditions
Solid Tumor
Interventions
DRUG

Disitamab vedotin

Disitamab Vedotin intravenously combined with radiotherapy (concurrent)

Trial Locations (1)

Unknown

RECRUITING

Shandong Cancer hospital &Institute, Jinan

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY